News Roundup: ACIP Recommends Pfizer Vaccine, FDA Delays Moderna EUA for Teens
Here’s a roundup of the latest news from Drug Topics®.
Expert Interview: NACDS CEO Steven Anderson on the Power of Association
Steven Anderson, CEO, NACDS, joined Drug Topics® for a forward look at how associations—like the National Association of Chain Drug Stores—can empower pharmacies through collaboration in 2022.
Drug Topics Salary Survey 2021
We need your opinions for the Drug Topics® 2021 Salary Survey.
Tell us about your workplace experience this year: from stress to compensation and everything in between, Finish the survey, and we’ll enter you into a drawing for 1 of 4 $100 Visa gift cards.* Take the survey now (*see survey rules for details.)
Prioritizing the Mental Health of Providers Across the Country
Susan Lorenz-Fisher, vice president of corporate responsibility & sustainability, AmerisourceBergen, and Erin Briggs, senior pharmacy advisor, Americares, discuss mental health awareness and resources for pharmacists to support their mental health.
In Unanimous Vote, ACIP Recommends Pfizer-BioNTech COVID-19 Vaccine for Children Ages 5 to 11
The next step in the approval process is the formal acceptance of the recommendation by CDC Director Rochelle P. Walensky, MD, MPH.
First Participant Enrolled in Trial for Vaccine to Treat Opioid Disorders
A vaccine that prevents oxycodone from entering the brain? This might be the safe, long-lasting, cost-effective solution for opioid use disorders.
FDA Delays Adolescent COVID-19 Vaccine EUA Announcement for Moderna Vaccine
The FDA has notified Moderna that it will need additional time to complete its evaluation of the company’s EUA request for the use of its COVID-19 vaccine at the 100 µg dose level in adolescents between 12 and 17 years.
